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Many persons infected with Toxoplasma gondii develop ocular lesions. Immunologic pa-
rameters in the response to T. gondii were evaluated in infected persons with and without
ocular lesions and in noninfected controls. Subjects were divided into groups on the basis of
presence of serum antibodies to T. gondii, presence of ocular lesions, and clinical history.
Production of interleukin-2 and interferon-g by peripheral blood mononuclear cells from
patients with probable congenital toxoplasmosis was decreased, compared with that in persons
with presumed acquired infection. Cell proliferation and delayed-type skin reaction induced
by soluble toxoplasma tachyzoite antigen followed the same pattern. Asymptomatic persons
showed high levels of interleukin-12 and interferon-g, whereas persons with ocular lesions
had high interleukin-1 and tumor necrosis factor-a responses toward soluble toxoplasma
tachyzoite antigen. These data suggest that patients with ocular disease due to congenital
infection show tolerance toward the parasite. Furthermore, susceptibility to ocular lesions
after acquired toxoplasmosis is associated with high levels of interleukin-1 and tumor necrosis
factor-a, whereas resistance is associated with high levels of interleukin-12 and interferon-g.
Toxoplasmosis is caused by the intracellular protozoan Toxo-
plasma gondii. Acquired disease may result in lymphadenop-
athy, low-grade fever, and sore throat. In general, the disease
progresses to a symptomless state in immunocompetent persons
[1]. Disease is often fatal in the immunocompromised host,
mostly because of encephalitis [2–5]. Ocular lesions are caused
by either congenital or acquired infection. In the United States,
infection occurs in 2/1000 pregnancies, with a transplacental
infection rate <50% [6]. Seventy percent of infants with con-
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genital infection show chorioretinal scars. Acquired disease was
thought to be rare [7, 8]. However, several studies indicate that
ocular lesions may be caused by T. gondii infection after birth
[1, 9–13]. Ocular toxoplasmosis is characterized by a necrotizing
retinitis with oval or circular lesions. Reactivation sites usually
appear in proximity to older atrophic lesions [8, 14, 15].
Recent clinical and epidemiologic studies indicate that 95%
of the population of Erechim, a region in southern Brazil, are
seropositive for T. gondii [1, 10]. Interestingly, 20% of Erechim’s
population develop ocular toxoplasmosis, most of which is
thought to be acquired [1, 10]. This population therefore offers
a unique opportunity to study the differences in the immune
response to toxoplasma antigens between infected persons with
or without ocular lesions and in persons with congenital disease.
We sought to distinguish between patients with congenital toxo-
plasmosis and those with acquired disease on the basis of their
lymphokine response toward T. gondii. We therefore studied
resistance and susceptibility to the development of ocular le-
sions in relation to differences in the patients’ cytokine profiles.
Methods
Patients. Blood samples were collected from 136 subjects 18–64
years old; sexes were equally represented. Twenty-six subjects had
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negative titers of antibody (IgM and IgG) to T. gondii (titer,
!1 : 4). All others had positive titers of antibody to toxoplasma
(IgM or IgG; 11 : 64). Antibody titers were evaluated by a test kit
(Sigma, St. Louis). Subjects came from Erechim or Sa˜o Paulo,
Brazil. Clinical status (presumed acquired ocular toxoplasmosis,
congenital ocular toxoplasmosis, or absence of ocular lesions) was
determined, as described elsewhere [1, 9, 10]. In brief, patients were
presumed to have acquired toxoplasmosis if they had had a fun-
duscopic examination with a clear fundus before the visit in which
disease was diagnosed, if their mother had a positive titer of IgG
antibody before pregnancy, or if they had an older sibling with
documented ocular toxoplasmosis. Patients were presumed to have
congenital toxoplasmosis leading to ocular lesions if their mother
had a positive IgM response to toxoplasma antigens during preg-
nancy and if, at their first visit to the ophthalmologist, ocular
lesions were visualized at the funduscopic examination.
Of note, all patients with probable congenital toxoplasmosis
studied had ocular lesions. No subject was receiving treatment with
any immunosuppressive or immunomodulatory drug. Women who
used oral contraceptives were not included in this study, because
these drugs may alter the antigen-specific response patterns of T
cells (authors’ unpublished data). Other drugs being used by the
patients during the time of the study included antibiotics (2 pa-
tients), aspirin (2 patients), acetaminophen (3 patients), and anti-
histamine (5 patients).
Proliferation assays. Proliferation assays were done as de-
scribed elsewhere [16]. In brief, peripheral blood mononuclear cells
(PBMCs), obtained by gradient centrifugation, were diluted to 106
cells/mL and added to 96-well flat-bottom microtiter plates (Fal-
con, Oxnard, CA). Cultures were stimulated with either 2.5 mg/mL
phytohemagglutinin (PHA) or 5 mg/mL soluble toxoplasma tachy-
zoite antigen (STAg) or control antigens (tuberculin purified protein
derivative [PPD] or tetanus toxoid), in a final volume of 200 mL
of RPMI 1640 per well, containing 5% AB1 pooled human serum.
PBMCs were cultured for 96 h and then pulsed with 0.5 mCi/well
[3H]thymidine and processed accordingly for standard gaseous or
liquid scintigraphy. Results are presented in stimulation index (SI)
units that represent the mean proliferation in counts per minute to
a given stimulus divided by the mean background proliferation of
unstimulated cells. SIs 12 were considered positive. PBMCs were
obtained from blood drawn 11 month after the last active episode
of disease and <2 months after the end of that episode.
Preparation of STAg. STAg was prepared as described else-
where [17]. In brief, tachyzoites of the RH strain were maintained
by in vitro passage in human foreskin fibroblasts at 377C. For
antigen preparation, tachyzoites were harvested from fibroblast cul-
tures, passed through a 27-gauge needle, centrifuged at 70 g for 5
min, and pelleted at 590 g for 10 min. Tachyzoites were then son-
icated 4 times for 20 s each round and centrifuged at 10,000 g for
30 min. The supernatant preparation, termed STAg, was used as
antigen in the in vitro assays.
Interleukin (IL) measurement. Human IL-2 was measured by
the proliferation of the murine indicator T cell line HT-2 or by
ELISA with paired antibody (PharMingen, San Diego). IL-1, IL-
4, IL-5, IL-6, IL-10, IL-12, tumor necrosis factor (TNF)–a, and
interferon (IFN)–g were also measured by ELISA as described
elsewhere [16].
Flow cytometry. Standard flow cytometry analysis was done
with antibodies to human Va and Vb chain (Endogen, Cambridge,
MA; or PharMingen). One million cells were stained directly in a
final volume of 100 mL of PBS, according to the manufacturer’s
instructions, and were read (FACScan with Lysis II software or
FACScallibur with CellQuest software; Becton Dickinson Im-
munocytometry Systems, San Jose, CA).
Reverse transcriptase–polymerase chain reaction (RT-PCR) anal-
ysis of Vb T cell receptor (TCR) chain. Analysis of the TCR by
RT-PCR was done as described elsewhere [18]. RNA from PBMCs
was obtained by the RNAzol B method, reverse-transcribed, and
amplified by use of primers described elsewhere [18]. PCR products
were separated on 1% agarose gels and analyzed by Southern blot
hybridization with fluorescein-labeled internal probes, using the
ECL-3′ oligolabeling and detection system and Hyperfilm (Amer-
sham, Buckinghamshire, UK).
Reagents. Ficoll-hypaque was obtained from Sigma; PHA was
obtained from Difco (Detroit). IL-2 was purchased from
Boehinger (Mannheim, Germany), human IL-4 and IFN-g were
purchased from Genzyme (Cambridge, MA); human IL-1, IL-12,
and TNF-a were obtained from R&D Systems (Minneapolis); and
human IL-10 and IL-5 were from PharMingen.
Statistical analysis. The significance of the data was deter-
mined by analysis of variance, Fisher’s paired least-square differ-
ence, and the Kruskal-Wallis test for nonparametric data. Results
were considered statistically significant when a 95% confidence level
was achieved.
Results
In a recent population-based household survey in Erechim,
184 (17.7%) of 1042 persons examined were considered to have
ocular toxoplasmosis [1, 3, 6, 9]. Because of the high frequency
of the disease [1, 3, 11], its occurrence in multiple siblings [1],
and its low prevalence in children, compared with individuals
113 years old [10], many of the ocular toxoplasmosis cases in
Erechim are thought to be sequelae of postnatal infection. This
population represents an ideal setting for the study of the dif-
ferences in the immune response between persons with acquired
and congenital disease, as well as the immune mechanisms re-
lated to resistance and susceptibility to the development of oc-
ular lesions. Patients who have been followed by some of us
(C.S. and R.B.) were grouped as follows: normal controls with
negative serology for toxoplasma, age- and sex-matched with
study subjects, patients with positive serology for T. gondii but
without ocular lesions, patients with a diagnosis of acquired
ocular toxoplasmosis, and patients with a diagnosis of con-
genital ocular toxoplasmosis.
In vitro immune response to toxoplasma antigens. Figure 1
shows the stimulation indices obtained when PBMCs from the
different groups were cultured in the presence of STAg. Al-
though some seronegative persons had positive proliferative
responses (SI >2), most persons from that group did not re-
spond to toxoplasma antigens. In contrast, PBMCs from sero-
positive persons, irrespective of the presence of ocular lesions,
proliferated significantly in response to STAg. Nevertheless,
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Figure 1. Peripheral blood mononuclear cell proliferation to soluble
toxoplasma tachyzoite antigen. Dashed line indicates limit above which
stimulation indices (SIs) are considered positive (control median 1 SD,
0.9 1 2.0). Horizontal line for each group represents median SI for
that group: 0.9, 5.4, 18, and 2.3 for seronegative (n = 26), seropositive
without ocular lesions (n = 40), presumed acquired ocular toxoplas-
mosis (n = 40), and probable congenital toxoplasmosis (n = 30), re-
spectively. Average SI to phytohemagglutinin was 29.8, 25.6, 21.0, and
30.1, respectively. Proliferation was measured at 48 h, and antigen-
specific proliferation was measured at 96 h. Average SI to tuberculin
purified protein derivative was 10.6, 11.9, 13.7, and 12.1, respectively.
Average SI to tetanus toxoid was 9.9, 8.7, 8.5, and 10.0, respectively.
Table 1. Cytokine production in response to soluble toxoplasma











IFN-g BL 7.96 (2.48) 2.27 (1.24) BL
TNF-a 0.86 (0.12) 2.9 (0.5) 8.77 (0.93) 6.02 (0.84)
IL-1 0.54 (0.09) 1.35 (0.4) 10.61 (4.8)a 5.56 (1.24)
IL-2 BL 0.33 (0.12) 0.49 (0.13) BL
IL-4 BL BL BL BL
IL-5 BL BL BL BL
IL-10 BL 0.05 (0.02) 0.09 (0.02) BL
IL-12 0.1 (0.01) 0.64 (0.08)b 0.22 (0.05) 0.26 (0.04)
NOTE. Data are ng/mL (SE). BL, below detection limit for assay. Detection
limits (expressed as pg/mL) were as follows: interferon-g (IFN-g), 10; tumor
necrosis factor-a (TNF-a), 20; interleukin-1 (IL-1), 40; IL-2, 10; IL-4, 50; IL-5,
20; IL-10, 50; IL-12 (p70), 20. Supernatants from cells obtained from the same
patients and stimulated with phytohemagglutinin, tuberculin purified protein de-
rivative, or tetanus toxoid showed cytokine levels above the detection limit, con-
firming that assays were adequate.
a Significantly higher ( ) than among seropositive asymptomatic patients.P ! .05
b Significantly higher ( ) than among patients with acquired disease.P ! .05
persons with a diagnosis of acquired ocular toxoplasmosis had
a median SI of 18, significantly higher than that of asympto-
matic persons (SI, 5.4). Interestingly, patients with congenital
toxoplasmosis had significantly lower SIs (median, 2.3) than
did those with acquired disease. There was no difference be-
tween the groups in response to PHA or unrelated antigens
(PPD and tetanus toxoid). Some patients from each group were
analyzed for skin delayed-type hypersensitivity response to
toxoplasma antigens, according to a protocol described else-
where [19]. Patients with acquired ocular toxoplasmosis showed
the strongest skin delayed-type hypersensitivity reaction elicited
by T. gondii antigens. In contrast, patients with congenital oc-
ular disease had no reaction to toxoplasma antigen in vivo (data
not shown). Because of the small number of patients whose
delayed-type hypersensitivity response was evaluated, the dif-
ferences between groups were not statistically significant. Nev-
ertheless, the finding that the in vitro PBMCs proliferation in
response to toxoplasma antigens differs between the group with
acquired disease and the group with congenital disease suggests
that these two different forms of disease, although clinically
indistinguishable, can be differentiated by a laboratory test. In
addition, it suggests that the immune response to parasite anti-
gens differs, depending on when the infection was acquired. To
further study this possibility, we analyzed the patterns of cyto-
kine response to toxoplasma antigens in the same groups de-
scribed above.
Cytokine profile in response to toxoplasma antigens. Pa-
tients with a diagnosis of acquired ocular toxoplasmosis had
significantly higher levels of IL-1 (P ! .05) than did asymp-
tomatic persons (table 1). TNF-a and IL-10 secretion in re-
sponse to STAg were also increased in patients with acquired
disease although the differences were not statistically significant
(table 1). On the other hand, asymptomatic persons secreted
significantly more IL-12 (P ! .05) than did patients with ac-
quired lesions. IFN-g levels also were higher in asymptomatic
persons than in patients with acquired toxoplasmosis. However,
the difference was not statistically significant. IL-4 and IL-5
were undetectable in all groups in response to STAg although
both cytokines could be detected in the supernatants from pa-
tient PBMCs stimulated with at least one of the control anti-
gens. In keeping with the lymphocyte proliferative responses,
lymphocyte-derived cytokine production in response to STAg
was lower in PBMCs from patients with congenital toxoplas-
mosis than in patients with acquired disease. Taken together,
these data suggest that patients with congenital disease develop
a degree of tolerance toward toxoplasma antigens. Whether
this tolerance is due to negative selection in the thymus or to
a peripheral mechanism is a question currently under investi-
gation in our laboratory. In addition, lymphocyte-derived cyto-
kines, such as IL-2 and IFN-g, are diminished in patients with
congenital disease in response to STAg, whereas macrophage-
derived cytokines, such as IL-1 and TNF-a, are overexpressed,
suggesting that different mechanisms may be involved in the
development of the ocular lesions. If indeed the mechanisms
underlying the development of chorioretinitis in patients with
acquired disease are different from those in patients with con-
genital disease, the therapeutic approach to these lesions should
also differ although the histopathologic characteristics and their
appearance on funduscopic examination are the same.
Because PBMCs from persons with congenital toxoplasmosis
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Table 2. Vb expression in peripheral blood mononuclear cells from









7 Vb5.1 (210), Vb8 (167)
8 None
9 Vb5.1 (202), Vb7 (135)
10 Vb5.1 (154), Vb6.7 (195)
11 Va12.1 (149)
12 None






19 Vb6.7 (123), Vb9 (200)
20 Vb5.1 (157)
21 Vb5.1 (132)
22 Vb5.1 (173), Vb6.7 (229)
23 None
24 Vb5.1 (139), Vb7.1 (213)
25 Vb5.1 (166), Vb9 (191)
26 None
NOTE. Data are Vb receptor (% increase in expression over unstimulated
cells). Va or Vb was considered enhanced if no. of positive cells after exposure
to soluble toxoplasma tachyzoite antigen was >2-fold higher than the no. of cells
bearing the same Va or Vb in cultures without stimulation.
showed a degree of hyporesponsiveness in vivo and in vitro,
we addressed the possibility that in these persons, T cells that
respond to toxoplasma antigens were deleted early during on-
togeny. Therefore, PBMCs from patients with congenital toxo-
plasmosis were analyzed for deletions of specific Vb-bearing
lymphocytes. The presence of Vb families was tested by flow
cytometry, when antibodies were available, or by RT-PCR, for
the Vb families against which antibodies are not available. De-
letions of Vb3, Vb12, Vb14, and Vb15 were observed. One patient
had a deletion of Vb5.1 cells to !0.5% by flow cytometry (data
not shown). However, some patients did not show any gaps in
their Vb repertoire. The Vb deletions found in patients with
congenital toxoplasmosis were often shared by members of the
same family, suggesting that these were familial variations that
were not due to the nature of the Toxoplasma infection. This
last finding is particularly important, because if specific T cells
are not deleted in patients with congenital toxoplasmosis, an-
other mechanism must account for the deficient immune re-
sponse they show against STAg. It is still possible that deletion
of STAg-specific T cells occurs and that the methods used to
evaluate TCR Va and Vb families are not sufficiently sensitive
to detect minor changes in these families. However, we must
consider that other mechanisms may be responsible for the
decrease in proliferation and cytokine production seen in the
PBMCs from patients with congenital toxoplasmosis. Studies
are under way in our laboratory to investigate some of the
possible mechanisms involved.
TCR Vb expression. Studies in mice have suggested that T.
gondii contains a superantigen-like activity capable of selective
induction of T cells bearing the Vb5 chain both in vitro and in
vivo [20–22]. Because superantigen stimulation causes expan-
sion and ultimately deletion of the T cells bearing the TCRs
with which they interact [20–22], we hypothesized that if T.
gondii expresses a superantigen, exposure to STAg would result
in the expansion of T cells bearing specific Vb chains in sero-
negative persons. Therefore, we stimulated PBMCs from sero-
negative persons with STAg. Five days after stimulation, the
Va and Vb repertoire in culture was evaluated by flow cytometry
in comparison with the Va and Vb repertoire expressed by un-
stimulated cells. A Va or Vb was considered expanded if the
percentage of positive cells after stimulation was >2-fold higher
than the frequency in the unstimulated population. Nine of 26
seronegative persons tested showed an expansion of some T
cells bearing the Vb5.1 receptor (table 2). Increases in the per-
centage of T cells expressing Vb5.2/Vb5.3, Vb6.7, Vb7.1, Vb8,
Vb9, and Vb23 were also found. One patient showed a significant
expansion of Va12.1-bearing cells. The fact that T cells from
unexposed persons proliferate in response to STAg supports
the hypothesis that a superantigen expressed by T. gondii is
capable of stimulating human T cells. This hypothesis is further
supported by the finding that such proliferation is made
through the expansion of specific Vb-bearing T cells. Interest-
ingly, one of the Vb families that is found expanded in patients
after stimulation with STAg is the same as the one seen ex-
panded in response to Toxoplasma stimulation in the mouse
[21, 22]. However, we found no evidence of specific Vb family
expansion in ex vivo PBMCs from persons with congenital
ocular toxoplasmosis or acquired ocular toxoplasmosis or from
asymptomatic seropositive persons.
Discussion
We have shown that patients with acquired ocular toxoplas-
mosis have higher T cell responses on stimulation with toxo-
plasma antigens than do seropositive asymptomatic persons.
In addition, persons with acquired toxoplasmosis secreted
higher amounts of IL-1, TNF-a, and IL-10 than did the asymp-
tomatic group. The synthesis of such cytokines elicited by the
parasite in the ocular tissues could account in part for the
pathogenesis of the lesions. In addition, our data suggest that
resistance to infection may be linked to the ability to secrete
high levels of IL-12. These data are in line with previous results
in the animal model of toxoplasmosis, showing that susceptible
mouse strains express high levels of cytokine mRNAs in the
eye [12, 13, 23]. Interestingly, patients with a diagnosis of con-
genital ocular toxoplasmosis had significantly lower lympho-
cyte proliferative responses and delayed-type hypersensitivity
skin reactions and secreted significantly less IL-2 and IFN-g in
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response to STAg than did patients with a diagnosis of acquired
ocular toxoplasmosis. The diminished response to toxoplasma
antigens by T cells from patients with congenital disease sug-
gests that T. gondii–specific T cells could have been deleted or
anergized through exposure to toxoplasma antigens during the
prenatal period. Analysis of expression of the Vb families in T
cells from these patients showed that the deletions in the T cell
repertoire were often shared by members of the same family
who did not have congenital toxoplasmosis. Although we can-
not rule out deletion as the cause of the decreased T cell re-
sponses, our data suggest that anergy may play an important
part in the unresponsiveness observed in T cells from patients
with congenital disease. Our findings are important because
they provide a laboratory tool to differentiate between acquired
and congenital disease, and they also suggest that the mecha-
nisms involved in the development of ocular lesions may be
different in the two forms of disease, despite the similarity in
the pathologic features.
Acknowledgments
We thank Anna Carla Goldberg for suggestions and Rachel R. Caspi
for critical manuscript review.
References
1. Silveira C, Belfort R Jr, Burnier M Jr, Nussenblatt R. Acquired toxoplasmic
infection as the cause of toxoplasmic retinochoroiditis in families. Am J
Ophthalmol 1988;106:362–4.
2. Bertoli F, Espino M, Arosemena JR, Fishback JL, Frenkel JK. A spectrum
in the pathology of toxoplasmosis in patients with acquired immunode-
ficiency syndrome. Arch Pathol Lab Med 1995;119:214–24.
3. Nussenblatt RB, Belfort R Jr. Ocular toxoplasmosis: an old disease revisited.
JAMA 1994;271:304–7.
4. Navia BA, Petito CK, Gold JWM, Cho ES, Jordan BD, Price RW. Cerebral
toxoplasmosis complicating the acquired immune deficiency syndrome:
clinical and neuropathologic findings in 27 patients. Ann Neurol 1986;
19:224–38.
5. Luft BJ, Brooks RG, Conley FK, McCabe RE, Remington JS. Toxoplasmic
encephalitis in patients with acquired immune response deficiency syn-
drome. JAMA 1984;252:913–7.
6. Nussenblatt RB, Withcup SM, Palestine AG. Uveitis: fundamentals and clin-
ical practice. 2d ed. Vol 1. St. Louis: Mosby, 1996.
7. Perkins ES. Ocular toxoplasmosis. Bull Ophthalmol Soc Egypt 1967;60:
523–7.
8. Perkins ES. Toxoplasmosis [editorial]. Br Med J 1972;4:46.
9. Saari M, Vuorre I, Neiminen H, Raisanen S. Acquired toxoplasmic chorioret-
initis. Arch Ophthalmol 1976;94:1485–8.
10. Glasner PD, Silveira C, Kruszon-Moran D, et al. An unusually high prev-
alence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol
1992;114:136–44.
11. Brezin AP, Egwuagu CE, Burnier M Jr, et al. Identification of Toxoplasma
gondii in paraffin-embedded sections by the polymerase chain reaction.
Am J Ophthalmol 1990;110:599–604.
12. Gazzinelli RT, Brezin A, Li Q, Nussenblatt RB, Chan CC. Toxoplasma gondii:
acquired ocular toxoplasmosis in the murine model, protective role of
TNF-alpha and IFN-gamma. Exp Parasitol 1994;78:217–29.
13. Hayashi S, Chan CC, Gazzinelli RT, Pham NT, Cheung MK, Roberge FG.
Protective role of nitric oxide in ocular toxoplasmosis. Br J Ophthalmol
1996;80:644–8.
14. Perkins ES. Ocular toxoplasmosis. Br J Ophthalmol 1973;57:1–17.
15. Chan CC, Palestine AG, Li Q, Nussenblatt RB. Diagnosis of ocular toxo-
plasmosis by the use of immunocytology and the polymerase chain re-
action [letter]. Am J Ophthalmol 1994;117:803–5.
16. Correˆa-Sales C, Tosta CE, Rizzo LV. The effects of anesthesia with thiopental
on T lymphocyte responses to antigen and mitogens in vivo and in vitro.
Int J Immunopharmacol 1997;19:1117–28.
17. Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A. Synergistic role of
CD41 and CD81 T lymphocytes in IFN-gamma production and protective
immunity induced by an attenuated Toxoplasma gondii vaccine. J Im-
munol 1991;146:286–92.
18. Cunha-Neto E, Moliterno R, Coelho V, et al. Restricted heterogeneity of T
cell receptor variable alpha chain transcripts in hearts of Chagas’ disease
cardiomyopathy patients. Parasite Immunol 1994;16:171–9.
19. Belfort R Jr, Moura NC, Akira Omi C, Tsunechiro J, Abreu MT, Mendes
NF. Imunidade tardia (hipersensibilidade cutaˆnea tardia) especı´fica e ines-
pecı´fica em uveı´tes. Arq Bras Oftalmol 1983;46:2–4.
20. Denkers EY, Caspar P, Hieny S, Sher A. Toxoplasma gondii infection induces
specific nonresponsiveness in lymphocytes bearing the V beta 5 chain of
the mouse T cell receptor. J Immunol 1996;156:1089–94.
21. Denkers EY, Caspar P, Sher A. Toxoplasma gondii possesses a superantigen
activity that selectively expands murine T cell receptor V beta 5–bearing
CD81 lymphocytes. J Exp Med 1994;180:985–94.
22. Denkers EY, Sher A, Gazzinelli RT. CD81 T-cell interactions with Toxo-
plasma gondii: implications for processing of antigen for class I–restricted
recognition. Res Immunol 1993;144:51–7.
23. Amichay D, Gazzinelli RT, Karupiah G, Moench TR, Sher A, Farber JM.
Genes for chemokines MuMig and Crg-2 are induced in protozoan and
viral infections in response to IFN-gamma with patterns of tissue ex-
pression that suggest nonredundant roles in vivo. J Immunol 1996;157:
4511–20.
 at Escola Paulista M
edicina on O
ctober 15, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
